Nature Communications (Oct 2019)

High-potency ligands for DREADD imaging and activation in rodents and monkeys

  • Jordi Bonaventura,
  • Mark A. G. Eldridge,
  • Feng Hu,
  • Juan L. Gomez,
  • Marta Sanchez-Soto,
  • Ara M. Abramyan,
  • Sherry Lam,
  • Matthew A. Boehm,
  • Christina Ruiz,
  • Mitchell R. Farrell,
  • Andrea Moreno,
  • Islam Mustafa Galal Faress,
  • Niels Andersen,
  • John Y. Lin,
  • Ruin Moaddel,
  • Patrick J. Morris,
  • Lei Shi,
  • David R. Sibley,
  • Stephen V. Mahler,
  • Sadegh Nabavi,
  • Martin G. Pomper,
  • Antonello Bonci,
  • Andrew G. Horti,
  • Barry J. Richmond,
  • Michael Michaelides

DOI
https://doi.org/10.1038/s41467-019-12236-z
Journal volume & issue
Vol. 10, no. 1
pp. 1 – 12

Abstract

Read online

Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) are a powerful tool for neuroscience, but the standard DREADD ligand, CNO, has significant drawbacks. Here the authors report two novel high-potency DREADD ligands and a novel DREADD radiotracer for imaging purposes.